Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention

详细信息    查看全文

• 作者：Leslee J. Shaw ; William S. Weintraub ; David J. Maron ; Pamela M. Hartigan ; Rory Hachamovitch ; James K. Min ; Marcin Dada ; G.B. John Mancini ; Sean W. Hayes ; Robert A. O'Rourke ; John A. Spertus ; William Kostuk ; Gilbert Gosselin ; Bernard R. Chaitman ; Merill Knudtson ; John Friedman ; Piotr Slomka ; Guido Germano ; Eric R. Bates ; Koon K. Teo ; et al.
• 刊名：American Heart Journal
• 出版年：2012
• 出版时间：August, 2012
• 年：2012
• 卷：164
• 期：2
• 页码：243-250
• 全文大小：288 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

The COURAGE trial reported similar clinical outcomes for patients with stable ischemic heart disease (SIHD) receiving optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI). The current post hoc substudy analysis examined the relationship between baseline stress myocardial ischemia and clinical outcomes based on randomized treatment assignment.

Methods

A total of 1,381 randomized patients (OMT n = 699, PCI + OMT n = 682) underwent baseline stress myocardial perfusion single-photon emission computed tomographic imaging. Site investigators interpreted the extent of ischemia by the number of ischemic segments using a 6-segment myocardial model. Patients were divided into those with no to mild (< 3 ischemic segments) and moderate to severe ischemia (¡Ý 3 ischemic segments). Cox proportional hazards models were calculated to assess time to the primary end point of death or myocardial infarction.

Results

At baseline, moderate to severe ischemia occurred in more than one-quarter of patients (n = 468), and the incidence was comparable in both treatment groups (P = .36). The primary end point, death or myocardial infarction, was similar in the OMT and PCI + OMT treatment groups for no to mild (18 % and 19 % , P = .92) and moderate to severe ischemia (19 % and 22 % , P = .53, interaction P value = .65). There was no gradient increase in events for the overall cohort with the extent of ischemia.

Conclusions

From the COURAGE trial post hoc substudy, the extent of site-defined ischemia did not predict adverse events and did not alter treatment effectiveness. Currently, evidence supports equipoise as to whether the extent and severity of ischemia impact on therapeutic effectiveness.